CASI Pharmaceuticals Secures FDA Clearance for CID-103 IND Application in Renal Allograft Antibody-Mediated Rejection

Reuters

08/04

CASI Pharmaceuticals Secures FDA Clearance for CID-103 IND Application in Renal Allograft Antibody-Mediated Rejection

CASI Pharmaceuticals Inc. has announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug $(IND.AU)$ application for CID-103, an anti-CD38 monoclonal antibody intended to treat renal allograft antibody-mediated rejection $(AMR)$. This clearance marks a significant milestone for CASI Pharmaceuticals, a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for organ transplant rejection and autoimmune diseases. The upcoming Phase 1 clinical trial will focus on evaluating the safety, tolerability, and efficacy of CID-103 in adults with active and chronic active renal allograft AMR. The study aims to address the urgent need for new therapeutic options for patients with resistant AMR, a leading cause of kidney transplant loss.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CASI Pharmaceuticals Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1056000) on August 04, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2556138384"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2556138384\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2556138384?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-04 21:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2556138384","market":"us","top_or_hot":-1,"title":"CASI Pharmaceuticals Secures FDA Clearance for CID-103 IND Application in Renal Allograft Antibody-Mediated Rejection","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      CASI Pharmaceuticals Secures FDA Clearance for CID-103 IND Application in Renal Allograft Antibody-Mediated Rejection\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        CASI Pharmaceuticals Inc. has announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug <a href=\"https://laohu8.com/S/IND.AU\">$(IND.AU)$</a> application for CID-103, an anti-CD38 monoclonal antibody intended to treat renal allograft antibody-mediated rejection <a href=\"https://laohu8.com/S/AMR\">$(AMR)$</a>. This clearance marks a significant milestone for CASI Pharmaceuticals, a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for organ transplant rejection and autoimmune diseases. The upcoming Phase 1 clinical trial will focus on evaluating the safety, tolerability, and efficacy of CID-103 in adults with active and chronic active renal allograft AMR. The study aims to address the urgent need for new therapeutic options for patients with resistant AMR, a leading cause of kidney transplant loss.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CASI Pharmaceuticals Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1056000) on August 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CASI Pharmaceuticals Secures FDA Clearance for CID-103 IND Application in Renal Allograft Antibody-Mediated Rejection</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCASI Pharmaceuticals Secures FDA Clearance for CID-103 IND Application in Renal Allograft Antibody-Mediated Rejection\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-08-04 21:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      CASI Pharmaceuticals Secures FDA Clearance for CID-103 IND Application in Renal Allograft Antibody-Mediated Rejection\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        CASI Pharmaceuticals Inc. has announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug <a href=\"https://laohu8.com/S/IND.AU\">$(IND.AU)$</a> application for CID-103, an anti-CD38 monoclonal antibody intended to treat renal allograft antibody-mediated rejection <a href=\"https://laohu8.com/S/AMR\">$(AMR)$</a>. This clearance marks a significant milestone for CASI Pharmaceuticals, a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for organ transplant rejection and autoimmune diseases. The upcoming Phase 1 clinical trial will focus on evaluating the safety, tolerability, and efficacy of CID-103 in adults with active and chronic active renal allograft AMR. The study aims to address the urgent need for new therapeutic options for patients with resistant AMR, a leading cause of kidney transplant loss.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CASI Pharmaceuticals Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1056000) on August 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CASI","symbol_name":"凱信遠達","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250804:nNDL9RcsWh:1","article_id":"2556138384","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2556138384","pubTimestamp":1754312436,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"CASI Pharmaceuticals Inc. has announced that the U.S. Food and Drug Administration  has cleared its Investigational New Drug  application for CID-103, an anti-CD38 monoclonal antibody intended to treat renal allograft antibody-mediated rejection . This clearance marks a significant milestone for CASI Pharmaceuticals, a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for organ transplant rejection and autoimmune diseases. The upcoming Phase 1 clinical trial will focus on evaluating the safety, tolerability, and efficacy of CID-103 in adults with active and chronic active renal allograft AMR. The study aims to address the urgent need for new therapeutic options for patients with resistant AMR, a leading cause of kidney transplant loss.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational pur","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CASI":"凯信远达","BK4139":"生物科技"},"translate_title":"CASI Pharmaceuticals获得FDA批准CID-103 IND申请治疗同种异体肾移植抗体介导的排斥反应","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CASI":0.9},"content_text":"CASI Pharmaceuticals Secures FDA Clearance for CID-103 IND Application in Renal Allograft Antibody-Mediated Rejection\n    \n\n        CASI Pharmaceuticals Inc. has announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug $(IND.AU)$ application for CID-103, an anti-CD38 monoclonal antibody intended to treat renal allograft antibody-mediated rejection $(AMR)$. This clearance marks a significant milestone for CASI Pharmaceuticals, a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for organ transplant rejection and autoimmune diseases. The upcoming Phase 1 clinical trial will focus on evaluating the safety, tolerability, and efficacy of CID-103 in adults with active and chronic active renal allograft AMR. The study aims to address the urgent need for new therapeutic options for patients with resistant AMR, a leading cause of kidney transplant loss.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CASI Pharmaceuticals Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1056000) on August 04, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}